Tag: drug

Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique.

Discover how CrazyBulk’s muscle building pills are redefining strength training programs and helping athletes gain muscle mass faster in 2025.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options

Washington, DC, July 19, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/07/19/week-26-in-americas-rebirth/

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –